title: [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
abstract: OBJECTIVE
  To assay correlation between primary resistance/sensitivity in vitro by MTT test in solid tumor and ascitic fluid and clininical outcome in ovarian cancer patients.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.
  
  
  METHODS
  MTT - (3-(4,5 - Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) chemosensitivity assay was performed in 45 samples of ovarian cancer tissue and 26 samples of ascitic fluid in ovarian cancer patients. We studied the in vitro drug resistance profiles of ovarian cancer specimens exposed to cisplatin, carboplatin, paclitaxel, topotecan, gemcitabin, etoposid.
  
  
  RESULTS
  The highest incidence of primary drug resistance in vitro had gemcitabin and carboplatin and the lowest incidence of primary drug resistance had cisplatin and topotecan. Cisplatin had lower incidence of primary drug resistance in vitro than carboplatin. Grade and stage of epithelial ovarian cancer did not correlate to the primary drug resistance/sensitivity in vitro in ovarian cancer patients. The histological subtype of epithelial ovarian cancer correlated to the resistance and sensitivity to chemotherapeutic agents in vitro. Ovarian cancer patients with primary drug resistance to paclitaxel and carboplatin in vitro had more complications during primary chemotherapy, shorter progression free interval and worse prognosis of the disease.
  
  
  CONCLUSIONS
  The lowest incidence of primary drug resistance in vitro had cisplatin. Ovarian cancer patients with in vitro resistance to paclitaxel and carboplatin had significantly higher risk for progression of disease when treated with standard platinum-paclitaxel based regimens. The primary resistance/sensitivity assay would contribute to the targeted treatment and better prognosis of ovarian cancer patients.
authors.affiliation: Porodnická a gynekologická klinika LF UK a Fakultní nemocnice Hradec Králové. sedlakiva@seznam.cz
authors.forename: I
authors.initials: I
authors.lastname: Sedláková
authors.forename: J
authors.initials: J
authors.lastname: Tosner
authors.forename: M
authors.initials: M
authors.lastname: Cervinka
authors.forename: K
authors.initials: K
authors.lastname: Brigulová
authors.forename: A
authors.initials: A
authors.lastname: Rezác
authors.forename: J
authors.initials: J
authors.lastname: Spacek
authors.forename: J
authors.initials: J
authors.lastname: Laco
authors.forename: P
authors.initials: P
authors.lastname: Skapinec
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents